RecruitingPhase 1NCT06596473

A Study of BG-C477 in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors

Sponsor

BeOne Medicines

Enrollment

310 participants

Start Date

Oct 3, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BG-C477, a drug called Chemotherapy, and others for people with advanced solid tumors. The study is currently recruiting participants at 54 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBG-C477

Administered intravenously.

DRUGTislelizumab

Administered intravenously.

DRUGChemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Locations(54)

City of Hope Phoenix Cancer Center

Goodyear, Arizona, United States

City of Hope National Medical Center

Duarte, California, United States

University of Colorado Cancer Center

Aurora, Colorado, United States

Yale University Yale Cancer Center

New Haven, Connecticut, United States

Osf Saint Francis Medical Center

Peoria, Illinois, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, New Jersey, United States

The University of Texas Md Anderson Cancer Center

Houston, Texas, United States

Texas Oncology Longview

Longview, Texas, United States

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Northern Beaches Hospital

Frenchs Forest, New South Wales, Australia

Sunshine Coast University Private Hospital

Birtinya, Queensland, Australia

Cancer Research South Australia

Adelaide, South Australia, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

One Clinical Research

Nedlands, Western Australia, Australia

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Beijing Chest Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Sun Yat Sen University Cancer Center

Guangzhou, Guangdong, China

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

Guangxi Medical University Cancer Hospital Wuxiang Branch

Nanning, Guangxi, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Jiamusi Cancer Hospital

Jiamusi, Heilongjiang, China

Henan Cancer Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China

The First Affiliated Hospital of Nanchang University Branch Xianghu

Nanchang, Jiangxi, China

The First Hospital of China Medical University

Shenyang, Liaoning, China

Jining No1 Peoples Hospital East Branch

Jining, Shandong, China

Linyi Peoples Hospital Beicheng Branch

Linyi, Shandong, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Yunnan Cancer Hospital

Kunming, Yunnan, China

The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan

Hangzhou, Zhejiang, China

Taizhou Hospital of Zhejiang Province (East)

Taizhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Kansai Medical University Hospital

Hirakata, Osaka, Japan

Shizuoka Cancer Center

Suntogun, Shizuoka, Japan

Tokyo Metropolitan Komagome Hospital

Bunkyoku, Tokyo, Japan

Cancer Institute Hospital of Jfcr

Kotoku, Tokyo, Japan

Hospital Wanita Dan Kanak Kanak Sabah (Hospital Likas)

Kota Kinabalu Sabah, Malaysia

Hospital Kuala Lumpur

Kuala Lumpur, Malaysia

Sarawak General Hospital

Kuching, Malaysia

Sunway Medical Centre

Petaling Jaya, Malaysia

National Cancer Institute (Institut Kanser Negara)

Putrajaya, Malaysia

Auckland City Hospital

Auckland, New Zealand

Siriraj Hospital

Bangkok, Thailand

Srinagarind Hospital (Khon Kaen University)

Muang, Thailand

King Chulalongkorn Memorial Hospital (Chulalongkorn University)

Pathum Wan, Thailand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06596473

Related Trials

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

NCT064455174 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT042224132 locations

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

NCT0717291911 locations

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT074603758 locations

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT0571955815 locations